Venture Visionary Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Venture Visionary Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-170	Closed	-$100K	–	1292
2022 Q2	$100K	Buy	+170	New	+$111K	0.01%	604
2022 Q1	–	Sell	-1,630	Closed	-$1.03M	–	530
2021 Q4	$1.03M	Sell	1,630 -52	-3%	-$32K	0.07%	221
2021 Q3	$1.02M	Buy	1,682 +204	+14%	+$127K	0.07%	217
2021 Q2	$825K	Buy	+1,478	New	+$749K	0.07%	230

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Venture Visionary Partners's REGN Position: Q3 2022 in Review

Venture Visionary Partners sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 170 shares — an estimated $100K sold.

Venture Visionary Partners first reported a position in REGN in Q2 2021 and held it in 4 quarters. The position peaked at $1.03M in Q4 2021. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Venture Visionary Partners reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Venture Visionary Partners sold 170 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $100K.
Venture Visionary Partners first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 4 quarters.
Venture Visionary Partners's Regeneron Pharmaceuticals position peaked at $1.03M in Q4 2021.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Venture Visionary Partners's 13F filing for Q3 2022, filed 14 Nov 2022.